International Stem Cell Corporation develops an alternative stem cell treatment for Parkinson’s disease

Written by Elena Conroy

The National Institute of Health describes the future of regenerative medicine as a world where there is no donor organ shortage, victims of spinal cord injuries can walk and weakened hearts are successfully replaced. To achieve the promise of this revolutionary treatment option it is necessary to successfully overcome the barriers associated with immune response, which have severely hindered the advancement of cell replacement therapies thus far. International Stem Cell Corporation (ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, is addressing this limitation through the development of its ground-breaking parthenogenesis stem cell technology. Parthenogenesis utilizes...

To view the full article, please register now for access

It's completely free